Novartis (NVS) announced Coartem Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. “The new treatment, also known as Riamet Baby in some countries, was developed in collaboration with Medicines for Malaria Venture to treat the potentially deadly mosquito-borne disease. Eight African countries also participated in the assessment and are now expected to issue rapid approvals under the Swiss agency’s Marketing Authorization for Global Health Products procedure. Novartis plans to introduce the infant-friendly treatment on a largely not-for-profit basis to increase access in areas where malaria is endemic,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- GSK completes acquisition of efimosfermin alfa from Boston Pharmaceuticals
- Novartis’ RED4MS Trial: A New Hope for Multiple Sclerosis Treatment?
- Novartis reports GCAptAIN study did not meet primary endpoint
- Novartis: Strong Growth and Product Performance Amid Valuation Concerns and Generic Competition Risks
- PFE, NVS, and JNJ: The Shining Stars of the Sluggish Healthcare Sector